Mayo Clinic Study Uses IBL-America's Amyloid Beta ELISA

Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer’s disease

Accumulation of amyloid-β peptides is a dominant feature in the pathogenesis of Alzheimer’s disease; however, it is not clear how individual amyloid-β species accumulate and affect other neuropathological and clinical features in the disease. Thus, we compared the accumulation of N-terminally truncated amyloid-β and full-length amyloid-β, depending on disease stage as well as brain area, and determined how these amyloid-β species respectively correlate with clinicopathological features of Alzheimer’s disease. To this end, the amounts of amyloid-β species and other proteins related to amyloid-β metabolism or Alzheimer’s disease were quantified by enzyme-linked immunosorbent assays (ELISA)...Read more

Learn more about our Amyloid Beta 1-40 and 1-42 (FL) assays:

Amyloid Beta ( 1-40 ) ( FL ) Aβ

Amyloid Beta ( 1-42 ) ( FL ) Aβ